# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-26-004409
**Filing Date:** 2026-5
**Character Count:** 8999
**Document Hash:** ec6f0cde987ce7a7528b03573ccd7c10
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-004409.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001654954-26-004409

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260506

**FILED AS OF DATE**: 20260506

**DATE AS OF CHANGE**: 20260506

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 26947506

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

 **UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May 2026

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **79 New Oxford Street, London, WC1A 1DG**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 6 May 2026, London UK

 **Results of 26<sup>th</sup> Annual General Meeting**

GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 6 May 2026 at the London Marriott Hotel Grosvenor Square, Grosvenor Square, London, W1K 6JP. Shareholders were able to join the meeting in person or virtually via the Lumi Global website and Zoom.

All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.

All 25 resolutions were passed and decided upon by a poll. The table below shows the results for each resolution. The full text of the resolutions is contained in the Notice of AGM published on 25 March 2026, which is available on GSK's website at <u>www.gsk.com</u>.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Resolution** | **Resolution** | **Total votes for**<sup>(1)(2)</sup> | **%** | **Total votes against**<sup>(2)</sup> | **%** | **Total votes cast** | **% of Issued Share Capital voted**<sup>(3)</sup> | **Votes withheld**<sup>(4)</sup> |
| 1 | Receive and adopt the 2025 Annual Report | 3073839952 | 99.25 | 23182191 | 0.75 | 3097022143 | 76.38% | 8652004 |
| 2 | Approve the Annual report on remuneration  | 2986046185 | 96.74 | 100644457 | 3.26 | 3086690642 | 76.12% | 18986231 |
| 3 | Approve the Remuneration policy | 3066582993 | 98.96 | 32182945 | 1.04 | 3098765938 | 76.42% | 6914570 |
| 4 | Election of Luke Miels | 3081325569 | 99.37 | 19501818 | 0.63 | 3100827387 | 76.47% | 4845132 |
| 5 | Re-election of Sir Jonathan Symonds | 3079744123 | 99.32 | 21127306 | 0.68 | 3100871429 | 76.47% | 4793341 |
| 6 | Re-election of Julie Brown | 3069722312 | 99.00 | 31102814 | 1.00 | 3100825126 | 76.47% | 4848203 |
| 7 | Re-election of Elizabeth McKee Anderson | 3042023812 | 98.52 | 45732363 | 1.48 | 3087756175 | 76.15% | 17906882 |
| 8 | Re-election of Charles Bancroft | 3070002110 | 99.43 | 17646639 | 0.57 | 3087648749 | 76.15% | 18018954 |
| 9 | Re-election of Dr Hal Barron | 3080985163 | 99.37 | 19595495 | 0.63 | 3100580658 | 76.47% | 5088510 |
| 10 | Re-election of Dr Anne Beal | 3048091490 | 98.71 | 39715257 | 1.29 | 3087806747 | 76.15% | 17858160 |
| 11 | Re-election of Wendy Becker | 3031625476 | 98.18 | 56091438 | 1.82 | 3087716914 | 76.15% | 17946122 |
| 12 | Re-election of Dr Harry C Dietz | 3094560703 | 99.80 | 6160152 | 0.20 | 3100720855 | 76.47% | 4943572 |
| 13 | Re-election of Dr Jeannie Lee | 3095593233 | 99.84 | 5084831 | 0.16 | 3100678064 | 76.47% | 4985598 |
| 14 | Re-election of Dr Gavin Screaton | 3095403626 | 99.83 | 5240337 | 0.17 | 3100643963 | 76.47% | 5019966 |
| 15 | Re-election of Dr Vishal Sikka | 3095036695 | 99.82 | 5513088 | 0.18 | 3100549783 | 76.47% | 5111280 |
| 16 | Re-appointment of the auditor | 3099113772 | 99.94 | 1891083 | 0.06 | 3101004855 | 76.48% | 4664323 |
| 17 | Remuneration of the auditor | 3098976181 | 99.94 | 1736335 | 0.06 | 3100712516 | 76.47% | 4949197 |
| 18 | Authority for the company to make donations to political organisations and incur political expenditure | 3039847574 | 98.91 | 33534985 | 1.09 | 3073382559 | 75.80% | 32288122 |
| 19 | Authority to allot shares | 2999108776 | 96.74 | 100960760 | 3.26 | 3100069536 | 76.45% | 5592295 |
| 20 | Disapplication of pre-emption rights - general power<sup>(5)</sup> | 3046584734 | 98.32 | 51962919 | 1.68 | 3098547653 | 76.42% | 7072535 |
| 21 | Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment<sup>(5)</sup> | 3059992748 | 98.75 | 38710772 | 1.25 | 3098703520 | 76.42% | 6947940 |
| 22 | Authority for the company to purchase its own shares<sup>(5)</sup> | 3093867095 | 99.82 | 5669416 | 0.18 | 3099536511 | 76.44% | 6127609 |
| 23 | Exemption from statement of senior statutory auditor's name | 3079861236 | 99.81 | 5739421 | 0.19 | 3085600657 | 76.10% | 20038163 |
| 24 | Authority for reduced notice of a general meeting other than an AGM<sup>(5)</sup> | 2911856203 | 93.98 | 186503587 | 6.02 | 3098359790 | 76.41% | 7285017 |
| 25 | Approve the amended Articles of Association<sup>(5)</sup> | 3065959469 | 99.40 | 18375929 | 0.60 | 3084335398 | 76.07% | 21304284 |

---

 **Notes:**

(1) The "for" votes include those giving the Chair discretion.

(2) Votes "for" and "against" are expressed as a percentage of the total votes cast.

(3) The Company's issued share capital as at 1 May 2026 consisted of **4,054,826,603** shares of 31 ¼ pence each ('Ordinary Shares') excluding Ordinary Shares held in Treasury. Every shareholder has one vote for every

Ordinary Share held.

(4) A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.

(5) Indicates Special Resolutions requiring a 75% majority of votes cast.

The following table provides further information on participation in the AGM:

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp; **GSK's 26<sup>th</sup> AGM**<br> **(Hybrid meeting)**<br> &nbsp;&nbsp;&nbsp;&nbsp; **(2026)** | &nbsp;&nbsp;&nbsp; **GSK's 25<sup>th</sup> AGM**<br> **(Hybrid meeting)**<br> &nbsp;&nbsp;&nbsp;&nbsp; **(2025)** |
| **Issued share capital (excluding Treasury Shares)** | &nbsp;&nbsp;&nbsp; 4054826603 | &nbsp;&nbsp;&nbsp; 4109037095 |
| **Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)** | &nbsp;&nbsp;&nbsp; 76.59% | &nbsp;&nbsp;&nbsp; 74.21% |
| **Total shareholder population** | &nbsp;&nbsp;&nbsp; 55305 | &nbsp;&nbsp;&nbsp; 57405 |
| **Total number of proxies lodged** | &nbsp;&nbsp;&nbsp; 2475 | &nbsp;&nbsp;&nbsp; 2617 |
| **Number of shareholders in attendance** | &nbsp;&nbsp;&nbsp; 117 in person<br> 17 participated virtually | &nbsp;&nbsp;&nbsp; 130 in person<br> 25 participated virtually |
| **% of shareholders who lodged proxies** | &nbsp;&nbsp;&nbsp; 4.48% | &nbsp;&nbsp;&nbsp; 4.56% |

---

The above poll results will shortly be available on the company's website at <u>www.gsk.com</u>.

In accordance with Listing Rule 6.4.2 of the Financial Conduct Authority's (FCA) Listing Rules, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the FCA and will, in due course, be available for inspection at <u>https://data.fca.org.uk/#/nsm/nationalstoragemechanism</u>

 **V A Whyte**

 **Company Secretary**

6 May 2026

 **About GSK**

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at <u>www.gsk.com</u>.

 **Registered in England & Wales:**

No. 3888792

 **Registered Office:**

79 New Oxford Stree

London

WC1A 1DG

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: May 06, 2026 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---